Cargando…

Optimal treatment for castration-resistant prostate cancer

Detalles Bibliográficos
Autores principales:	Izumi, Kouji, Namiki, Mikio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023386/ https://www.ncbi.nlm.nih.gov/pubmed/24759581 http://dx.doi.org/10.4103/1008-682X.126380

Ejemplares similares

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

Dexamethasone use in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: this “cort” is not out of order!
por: Van Praet, Charles, et al.
Publicado: (2021)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
por: Xu, Jin, et al.
Publicado: (2019)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Targeting hexokinase 2 in castration-resistant prostate cancer
por: Deng, Yibin, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Blood-based gene expression profiling in castrate-resistant prostate cancer
por: Gross, Mitchell E.
Publicado: (2015)

Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer
por: Gleicher, Stephanie, et al.
Publicado: (2021)

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
por: Merseburger, Axel S., et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
por: Izumi, Kouji, et al.
Publicado: (2017)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Separate Chinese lines for prostate cancer?
por: von Eyben, Finn Edler
Publicado: (2019)

Impact of IL-23 in prostate cancer
por: Mirlekar, Bhalchandra
Publicado: (2021)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Serum lipid profiles and aggressive prostate cancer
por: Li, Yanjing, et al.
Publicado: (2015)

Risk-prediction tools in prostate cancer: the challenge of tailoring
por: Morlacco, Alessandro, et al.
Publicado: (2016)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

New models for defining prostate cancer biology and patient prognosis
por: Brundage, James, et al.
Publicado: (2021)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

Findings from a prostate cancer screening program in a Japanese population
por: Ranasinghe, Weranja K B, et al.
Publicado: (2014)

Speckle-type POZ protein mutations in prostate cancer: a new part of the mosaic
por: Stoehr, Robert
Publicado: (2015)

Sexual dysfunction and prostate cancer risk: one more piece of a complex puzzle
por: Capogrosso, Paolo, et al.
Publicado: (2017)

Bacteria and the prostate: infertility versus symptoms
por: Pontari, Michel A
Publicado: (2014)

Extended lymph node dissection for intermediate and high-risk prostate cancer: do we have all the evidence?
por: Ghazi, Ahmed
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_29tqba26eu2ls44ajhcf44funo